Connect with us

Government

Five Biopharmaceutical Stocks to Buy for Profits Amid the Pandemic

Five biopharmaceutical stocks to buy offer investors a chance to profit while supporting companies that develop treatments for health problems through biological solutions. The five biopharmaceutical stocks to buy are part of an industry that generally…

Published

on

Five biopharmaceutical stocks to buy offer investors a chance to profit while supporting companies that develop treatments for health problems through biological solutions.

The five biopharmaceutical stocks to buy are part of an industry that generally is well-financed, with companies backed by an average of 3.5 years of cash to fund research and development (R&D) initiatives, compared to just 1.5 years at the peak of the 2008-09 financial crisis, according to BoA Global Research. Funding of biopharmaceutical stocks has risen dramatically since 2015, with more than $550 billion in cash amassed to keep these companies advancing their R&D programs, BoA reported in a June 29 research note.

Overall, global spending on medicines is projected to produce a 3-6% compound annual growth rate (CAGR) through 2025 to total about $1.6 trillion by 2025, excluding spending on COVID-19 vaccines, according to a recent report by the IQVIA Institute for Human Data Science (NYSE:IQV). The report, “The Global Spending and Usage of Medicines,” relied on invoice price levels to forecast total cumulative spending of $157 billion on COVID-19 vaccines through 2025 aimed largely at the initial wave of vaccinations to be completed by 2022.

In subsequent years, booster shots are expected to be required on a biannual basis, based on the length of immunity and the emergence of viral variants. Two therapy areas — oncology and immunology — each are forecast to grow at a 9-12% CAGR through 2025, spurred by sizable hikes in new treatments and medicine use, according to the institute.

Oncology Treatments Are Among Targets of the Five BioPharmaceutical Stocks to Buy

Oncology alone is expected to add 100 new treatments over five years, contributing to a rise in spending of more than $100 billion, totaling more than $260 billion in 2025. Immunology growth is projected to slow from its 17.3% CAGR of the past five years as reduced cost treatments offset growth in volume and drug launches. 

In addition, many new therapies are expected in neurology. Treatments also are slated for novel migraine therapies, rare neurological diseases and Alzheimer’s and Parkinson’s.

“Biotechnology stocks have been doing well recently, and that’s likely to continue,” said Bob Carlson, leader of the Retirement Watch investment newsletter. “Companies continue to announce breakthroughs, and a number of biotech companies are going public.”

Pension fund and Retirement Watch leader Bob Carlson answers questions from Paul Dykewicz.

Pension Fund Leader Likes Biotech ETFs as Alternative to Five Biopharmaceutical Stocks to Buy

It is “tough” to identify the best individual stocks in the biopharmaceutical sector, but Carlson said he would recommend a diversified exchange-traded fund (ETF) for most investors. However, even that is difficult, because of differences in the stocks held by the leading ETFs. The best move might be to hold positions in the two leading biotech ETFs, he concluded.

iShares Biotechnology (IBB) aims to track the NASDAQ Biotechnology Index, so it holds only stocks listed on the NASDAQ that are classified as either biotechnology or pharmaceutical companies, Carlson said. IBB tends to be the more volatile of the two funds, and over some periods its returns can be substantially higher or lower than alternatives, Carlson cautioned.

Despite the volatility, IBB gained 25.21% in 2019, 26.01% in 2020 and 7.79% so far in 2021. Its three-year annualized return is 14.24% and its five-year return is 14.71%, Carlson said.

Chart courtesy of www.StockCharts.com

SPDR S&P Biotech (XBI) Offers Another Path Aside from Five Biopharmaceutical Stocks to Buy

The other ETF Carlson recommended is SPDR S&P Biotech (XBI). That fund aims to track the S&P Biotechnology Select Industry Index. That sector index is derived from a U.S. total market composite, so it is not limited to S&P 500 stocks. But the fund uses a sampling strategy to try to track the index instead of holding all the stocks in the index.

“XBI tends to favor stocks with greater liquidity, so it doesn’t own many smaller companies or those with limited trading volume,” Carlson said.

Though it is less volatile than IBB, XBI is more volatile than the market indexes and the health care sector. The fund returned 32.56% in 2019 and 48.33% in 2020, but so far in 2021 it is down 1.46%. Plus, the fund’s annualized returns are 13.01% over three years and 21.94% for five years.

Chart courtesy of www.StockCharts.com

Five Biopharmaceutical Stocks to Buy Are a Challenge to Categorize

The difficulty of classifying stocks and funds in the biopharmaceutical sector is shown by Morningstar’s placement of these two funds in different categories, with IBB put in Specialty-Technology and XBI going in Specialty-Health.

IBB tends to hold larger capitalization companies than XBI. Despite their differences, Morningstar indicated the two funds have a high correlation of 94%, Carlson said.

Pharmaceutical stocks, in general, are attractive, since they trade at a historically low valuation to the S&P 500, Carlson said., They sell at a 40% discount to the S&P 500, even though many pharmaceutical companies have improving drug pipelines and attractive growth prospects, Carlson added.

Pharmaceutical stocks and funds have pulled back in recent months partly due to uncertainty about drug-pricing legislation in Washington, Carlson said. Some people are advocating that Medicare should be allowed to negotiate prices directly with the pharmaceutical companies to reduce drug prices.

Money Manager Kramer Indicates Five Biopharmaceutical Stocks to Buy Could Grow Mightily

“The real distinction for me at this point isn’t really about whether a drug developer draws on biotech materials or more conventional chemistry in order to treat illness,” said Hilary Kramer, who heads the GameChangers and Value Authority advisory services

The first standalone biotech companies that went public in the 1980s have grown to be able to go “toe-to-toe” with big pharmaceutical companies and, in some cases, are now integrated into industry behemoths, Kramer continued. For example, Celgene has been acquired by Bristol-Myers Squibb Inc. (NYSE:BMY), said Kramer, who also hosts the “Millionaire Maker” radio program.

“A few even pay dividends,” Kramer said.

Paul Dykewicz conducts a pre-COVID-19 interview with Hilary Kramer, whose premium advisory services include IPO Edge, 2-Day Trader, Turbo Trader and Inner Circle.

BoA Global Research Recommends Five Biopharmaceutical Stocks to Buy

Jazz Pharmaceuticals (NASDAQ:JAZZ) received a $223 price objective (PO) and a buy recommendation from BoA Global Research, based on a valuation of 10.5x enterprise value (EV)/earnings before interest, taxes, depreciation and amortization (EBITDA) projected in 2022. BoA’s valuation multiple shows confidence that JAZZ will navigate concerns about the expiration of certain patents and the company’s growth profile.

The EV/EBITDA multiple of 10.5x compares to the company’s peer group that trades at 9x, which BoA described as appropriate based on JAZZ’s growth outlook vs its rivals. However, JAZZ has risks that include possible slower-than-expected sales growth from its Vyxeos or Sunosi launches and weaker-than-expected sales growth of Xyrem, including failure to gain approval of next-generation formulations of Xyrem that could cause the pharmaceutical to lose its exclusivity prior to 2023.

Possible catalysts to help JAZZ exceed BoA’s price target include greater-than-expected sales growth from launching its Vyxeos chemotherapy or its narcolepsy treatment Sunosi. A second boost would be less-than-expected generic erosion of Xyrem (e.g., due to setbacks setting up a generic risk evaluation and mitigation strategy (REMS)), while a new plus would be future business development transactions becoming a key part of JAZZ’s strategy.

Chart courtesy of www.StockCharts.com

Five Biopharmaceutical Stocks to Buy Feature FibroGen

FibroGen Inc. (NASDAQ:FGEN) gained a $43 price objective from BoA, based on a risk-adjusted discounted cash flow (DCF) analysis. Risks that may prevent FibroGen from meeting that price target include underperformance of the launch of its chronic-kidney-disease-related anemia drug Roxadustat vs. BoA projections, low demand or reduced net pricing and competitor data proving to be superior in efficacy and safety.

Possible catalysts for FibroGen to exceed the BoA price target on the stock could take shape if Roxadustat launch beats forecasts, its labeling for cardiovascular risk and cancer tops expectations and its competitor data reveal weaker efficacy and safety profile. BoA also wrote FibroGen’s Pamrevlumab monoclonal antibody to treat idiopathic pulmonary fibrosis and pancreatic cancer achieves key clinical milestones in 2022-23.

BoA wrote on June 22 that Roxadustat clearly has demonstrated efficacy. Now, a key regulatory consideration will be the treatment’s safety and whether it meets historical statistical benchmarks, BoA added.

Chart courtesy of www.StockCharts.com

Arena Pharmaceuticals Wins Spot Among Five Biopharmaceutical Stocks to Buy

Arena Pharmaceuticals (NASDAQ:ARNA) earned a buy rating and a price objective of $87 from BoA, based on a risk-adjusted DCF analysis. In BoA’s DCF, it assumed sales forecasts through 2036 for Etrasimod, a once-daily, oral S1P1,4,5 modulator undergoing multiple phase 3 trials for moderate to severe ulcerative colitis. That BoA assessment included the expected loss of exclusivity (LOE) in 2034, assuming a five-year patent term extension. 

Risks that may prevent the company from achieving BoA’s price target include increased competition in Etrasimod’s target market to treat ulcerative colitis, if Ozanimod Ph3 clinical data to treat relapsing Multiple Sclerosis (MS) and inflammatory bowel disease substantially raise the bar for Etrasimod. Other risks could include Etrasimod failing to replicate Ph2 UC data in ongoing Ph3 and proving unable to demonstrate efficacy in Ph3 for atopic dermatitis, also known as eczema.

A reason for exceeding the price target may be Etrasimod producing impressive Ph3 data in treating atopic dermatitis, with clinical efficacy and safety similar to Dupixent, a prescription medicine used to treat people aged 6 and older who have moderate-to-severe eczema that is not well controlled. If so, Etrasimod may offer biologic-like efficacy but without the safety baggage of the Ph3 JAK inhibitors, according to BoA.

Chart courtesy of www.StockCharts.com

Five Biopharmaceutical Stocks to Buy List Applied Molecular Transport

BoA assigned Applied Molecular Transport Inc. (AMTI) a buy recommendation and a price objective of $68 per share, based on a risk-adjusted, sum-of-the-parts DCF analysis. The investment firm forecast AMTI would keep developing new drug candidates, while risk-adjusting for possibilities that the company may be unable to secure durable molecule-specific patents after expiration of intellectual properties. 

Possible risks to meeting the price target will include the outcome of Phase 2 clinical trials of AMT-101, a potential surprise emergence of competing platform for oral delivery of the treatment and possible dilution of existing shares issued at a discount.

Catalysts that could help the stock outperform expectations may include non-dilutive financing through a partnership or licensing that is not reflected in BoA’s forecast. Another catalyst would be a possible acquisition of the company at a premium price.

Chart courtesy of www.StockCharts.com

BeyondSpring Breaks into List of Five Biopharmaceutical Stocks to Buy

BeyondSpring Pharmaceuticals (NASDAQ:BYSI) received a buy rating and a $25 price objective from BoA, based on a risk-adjusted DCF analysis. The outlook hinged on key assumptions, including meeting cash flow forecasts through the 2036 patent life of Plinabulin, a small molecule under development and in a worldwide Phase 3 clinical trials to treat non-small-cell lung cancer. BoA projects that Plinabulin will produce $670 million in 2030 estimated risk-adjusted sales.

Possible risks to the company achieving the BoA price target could include a failure of Plinabulin to show desired results in clinical trials, slower-than-expected commercial uptake of that treatment in chemotherapy-induced neutropenia (CIN) and potentially dilutive cash raising efforts to commercialize the drug.

To outperform the price target, BeyondSpring might attain better-than-expected clinical data and commercial uptake of Plinabulin. The company also could be acquired at a premium price, according to BoA.

It is possible AMT-101 could produce the best in biologic efficacy and safety in its Phase 2 trial, according to BoA. That outperformance currently is not reflected in BoA’s market share model assumptions.

Chart courtesy of www.StockCharts.com

Kramer Offers Picks in Addition to the Five Biopharmaceutical Stocks to Buy

As for Kramer’s favorite biopharmaceutical stocks, she praised Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). All three stocks will give investors an experience similar to owning pharmaceutical goliaths, Kramer counseled. Those biotech stocks already have generated billions of dollars in wealth for their shareholders, but maybe they will triple or quadruple again in the lifetime of current investors on their way to becoming full-fledged industry giants, she added. 

Chart courtesy of www.StockCharts.com

Chart courtesy of www.StockCharts.com

Chart courtesy of www.StockCharts.com

“But if your idea of biotech investing revolves more around the thrill of early-stage companies plotting moon shots on complicated disease targets, you want to stay small, diversified and patient,” Kramer said. “I’ve been talking about CRISPR gene editing technologies for at least a decade. Now, some of the most advanced names in the field are finally working their way around to human beings. As long as you have the patience, you can never be too early in the baby biotech world. But you can be too late. Once the big clinical data release hits the market, you’ll never get the same chance to invest in an unproven quantity again.

“Take Intellia Therapeutics Inc. (NASDAQ:NTLA), for example. Unless something goes seriously wrong, we probably won’t get a lot of entry points below $100. Those days are gone. Instead, buy the names that are out of favor.”

Chart courtesy of www.StockCharts.com

Right now, Kramer said she loves Iova Biotherapeutics Inc. (NASDAQ:IOVA) and its new spin on fighting cancer. It could easily be a $100 stock again over time, she added.

Chart courtesy of www.StockCharts.com

“I haven’t given up on Bluebird Bio Inc. (NASDAQ:BLUE),” Kramer said. “Similar target; huge potential. Precision BioSciences Inc. (NASDAQ:DTIL), which has been a real sleeper but could one day both cure diseases and global hunger with a single genetic platform. Of course, it might take years if it happens at all, so stay diversified and resilient. But if you are in biotech, odds are good you want to aim high.”

Chart courtesy of www.StockCharts.com

Chart courtesy of www.StockCharts.com

Five Biopharmaceutical Stocks to Buy as New Variants of COVID-19 Spread

The increasingly transmissible Delta variant of COVID-19 has spread to almost every state in America, raising concerns among health officials about potential future spikes in cases. Genetic variants of SARS-CoV-2 have been emerging and circulating around the world throughout the COVID-19 pandemic, according to the Centers for Disease Control and Prevention (CDC).

A variant has one or more mutations that differentiate it from other variants in circulation. The Delta variant is expected to become the dominant coronavirus strain in the United States, the CDC director recently said. With more than half the U.S. population not fully vaccinated, public health officials caution that a resurgence of Covid-19 cases could occur in the fall when many unvaccinated children are expected to return to school.

Progress in the COVID-19 vaccination process lifts hope that new cases and deaths will keep dropping. So far, 179,940,202 people, or 54.2% of the U.S. population, have received at least one dose. Those fully vaccinated total 154,199,664 people, or 46.4%, of the U.S. population.

In addition, the Food and Drug Administration (FDA) recently approved a third COVID-19 vaccine, manufactured by Johnson & Johnson (NYSE:JNJ), which requires only one dose rather than two, as with the first two vaccine providers: Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA).

COVID-19 cases worldwide have hit 181,764,498 and caused 3,937,050 deaths, as of June 30, according to Johns Hopkins University. U.S. COVID-19 cases totaled 33,652,098 and have led to 604,474 deaths. America has the dubious distinction as the country with the most COVID-19 cases and deaths.

The five biopharmaceutical stocks to buy give investors ways to profit amid the pandemic while helping to fund the development of new treatments. Increased COVID-19 vaccine availability, an improving economy and a recent $1.9 trillion federal stimulus package should help to lift the valuations of the five biopharmaceutical stocks to buy.

Paul Dykewicz, www.pauldykewicz.com, is an accomplished, award-winning journalist who has written for Dow Jones, the Wall Street JournalInvestor’s Business DailyUSA Today, the Journal of Commerce, Seeking Alpha, GuruFocus and other publications and websites. Paul, who can be followed on Twitter @PaulDykewicz, is the editor of StockInvestor.com and DividendInvestor.com, a writer for both websites and a columnist. He further is editorial director of Eagle Financial Publications in Washington, D.C., where he edits monthly investment newsletters, time-sensitive trading alerts, free e-letters and other investment reports. Paul previously served as business editor of Baltimore’s Daily Record newspaper. Paul also is the author of an inspirational book, “Holy Smokes! Golden Guidance from Notre Dame’s Championship Chaplain,” with a foreword by former national championship-winning football coach Lou Holtz. The book is great as a gift and is endorsed by Joe Montana, Joe Theismann, Ara Parseghian, “Rocket” Ismail, Reggie Brooks, Dick Vitale and many others. Call 202-677-4457 for special Father’s Day gift pricing!

The post Five Biopharmaceutical Stocks to Buy for Profits Amid the Pandemic appeared first on Stock Investor.

Read More

Continue Reading

Government

Four Years Ago This Week, Freedom Was Torched

Four Years Ago This Week, Freedom Was Torched

Authored by Jeffrey Tucker via The Brownstone Institute,

"Beware the Ides of March,” Shakespeare…

Published

on

Four Years Ago This Week, Freedom Was Torched

Authored by Jeffrey Tucker via The Brownstone Institute,

"Beware the Ides of March,” Shakespeare quotes the soothsayer’s warning Julius Caesar about what turned out to be an impending assassination on March 15. The death of American liberty happened around the same time four years ago, when the orders went out from all levels of government to close all indoor and outdoor venues where people gather. 

It was not quite a law and it was never voted on by anyone. Seemingly out of nowhere, people who the public had largely ignored, the public health bureaucrats, all united to tell the executives in charge – mayors, governors, and the president – that the only way to deal with a respiratory virus was to scrap freedom and the Bill of Rights. 

And they did, not only in the US but all over the world. 

The forced closures in the US began on March 6 when the mayor of Austin, Texas, announced the shutdown of the technology and arts festival South by Southwest. Hundreds of thousands of contracts, of attendees and vendors, were instantly scrapped. The mayor said he was acting on the advice of his health experts and they in turn pointed to the CDC, which in turn pointed to the World Health Organization, which in turn pointed to member states and so on. 

There was no record of Covid in Austin, Texas, that day but they were sure they were doing their part to stop the spread. It was the first deployment of the “Zero Covid” strategy that became, for a time, official US policy, just as in China. 

It was never clear precisely who to blame or who would take responsibility, legal or otherwise. 

This Friday evening press conference in Austin was just the beginning. By the next Thursday evening, the lockdown mania reached a full crescendo. Donald Trump went on nationwide television to announce that everything was under control but that he was stopping all travel in and out of US borders, from Europe, the UK, Australia, and New Zealand. American citizens would need to return by Monday or be stuck. 

Americans abroad panicked while spending on tickets home and crowded into international airports with waits up to 8 hours standing shoulder to shoulder. It was the first clear sign: there would be no consistency in the deployment of these edicts. 

There is no historical record of any American president ever issuing global travel restrictions like this without a declaration of war. Until then, and since the age of travel began, every American had taken it for granted that he could buy a ticket and board a plane. That was no longer possible. Very quickly it became even difficult to travel state to state, as most states eventually implemented a two-week quarantine rule. 

The next day, Friday March 13, Broadway closed and New York City began to empty out as any residents who could went to summer homes or out of state. 

On that day, the Trump administration declared the national emergency by invoking the Stafford Act which triggers new powers and resources to the Federal Emergency Management Administration. 

In addition, the Department of Health and Human Services issued a classified document, only to be released to the public months later. The document initiated the lockdowns. It still does not exist on any government website.

The White House Coronavirus Response Task Force, led by the Vice President, will coordinate a whole-of-government approach, including governors, state and local officials, and members of Congress, to develop the best options for the safety, well-being, and health of the American people. HHS is the LFA [Lead Federal Agency] for coordinating the federal response to COVID-19.

Closures were guaranteed:

Recommend significantly limiting public gatherings and cancellation of almost all sporting events, performances, and public and private meetings that cannot be convened by phone. Consider school closures. Issue widespread ‘stay at home’ directives for public and private organizations, with nearly 100% telework for some, although critical public services and infrastructure may need to retain skeleton crews. Law enforcement could shift to focus more on crime prevention, as routine monitoring of storefronts could be important.

In this vision of turnkey totalitarian control of society, the vaccine was pre-approved: “Partner with pharmaceutical industry to produce anti-virals and vaccine.”

The National Security Council was put in charge of policy making. The CDC was just the marketing operation. That’s why it felt like martial law. Without using those words, that’s what was being declared. It even urged information management, with censorship strongly implied.

The timing here is fascinating. This document came out on a Friday. But according to every autobiographical account – from Mike Pence and Scott Gottlieb to Deborah Birx and Jared Kushner – the gathered team did not meet with Trump himself until the weekend of the 14th and 15th, Saturday and Sunday. 

According to their account, this was his first real encounter with the urge that he lock down the whole country. He reluctantly agreed to 15 days to flatten the curve. He announced this on Monday the 16th with the famous line: “All public and private venues where people gather should be closed.”

This makes no sense. The decision had already been made and all enabling documents were already in circulation. 

There are only two possibilities. 

One: the Department of Homeland Security issued this March 13 HHS document without Trump’s knowledge or authority. That seems unlikely. 

Two: Kushner, Birx, Pence, and Gottlieb are lying. They decided on a story and they are sticking to it. 

Trump himself has never explained the timeline or precisely when he decided to greenlight the lockdowns. To this day, he avoids the issue beyond his constant claim that he doesn’t get enough credit for his handling of the pandemic.

With Nixon, the famous question was always what did he know and when did he know it? When it comes to Trump and insofar as concerns Covid lockdowns – unlike the fake allegations of collusion with Russia – we have no investigations. To this day, no one in the corporate media seems even slightly interested in why, how, or when human rights got abolished by bureaucratic edict. 

As part of the lockdowns, the Cybersecurity and Infrastructure Security Agency, which was and is part of the Department of Homeland Security, as set up in 2018, broke the entire American labor force into essential and nonessential.

They also set up and enforced censorship protocols, which is why it seemed like so few objected. In addition, CISA was tasked with overseeing mail-in ballots. 

Only 8 days into the 15, Trump announced that he wanted to open the country by Easter, which was on April 12. His announcement on March 24 was treated as outrageous and irresponsible by the national press but keep in mind: Easter would already take us beyond the initial two-week lockdown. What seemed to be an opening was an extension of closing. 

This announcement by Trump encouraged Birx and Fauci to ask for an additional 30 days of lockdown, which Trump granted. Even on April 23, Trump told Georgia and Florida, which had made noises about reopening, that “It’s too soon.” He publicly fought with the governor of Georgia, who was first to open his state. 

Before the 15 days was over, Congress passed and the president signed the 880-page CARES Act, which authorized the distribution of $2 trillion to states, businesses, and individuals, thus guaranteeing that lockdowns would continue for the duration. 

There was never a stated exit plan beyond Birx’s public statements that she wanted zero cases of Covid in the country. That was never going to happen. It is very likely that the virus had already been circulating in the US and Canada from October 2019. A famous seroprevalence study by Jay Bhattacharya came out in May 2020 discerning that infections and immunity were already widespread in the California county they examined. 

What that implied was two crucial points: there was zero hope for the Zero Covid mission and this pandemic would end as they all did, through endemicity via exposure, not from a vaccine as such. That was certainly not the message that was being broadcast from Washington. The growing sense at the time was that we all had to sit tight and just wait for the inoculation on which pharmaceutical companies were working. 

By summer 2020, you recall what happened. A restless generation of kids fed up with this stay-at-home nonsense seized on the opportunity to protest racial injustice in the killing of George Floyd. Public health officials approved of these gatherings – unlike protests against lockdowns – on grounds that racism was a virus even more serious than Covid. Some of these protests got out of hand and became violent and destructive. 

Meanwhile, substance abuse rage – the liquor and weed stores never closed – and immune systems were being degraded by lack of normal exposure, exactly as the Bakersfield doctors had predicted. Millions of small businesses had closed. The learning losses from school closures were mounting, as it turned out that Zoom school was near worthless. 

It was about this time that Trump seemed to figure out – thanks to the wise council of Dr. Scott Atlas – that he had been played and started urging states to reopen. But it was strange: he seemed to be less in the position of being a president in charge and more of a public pundit, Tweeting out his wishes until his account was banned. He was unable to put the worms back in the can that he had approved opening. 

By that time, and by all accounts, Trump was convinced that the whole effort was a mistake, that he had been trolled into wrecking the country he promised to make great. It was too late. Mail-in ballots had been widely approved, the country was in shambles, the media and public health bureaucrats were ruling the airwaves, and his final months of the campaign failed even to come to grips with the reality on the ground. 

At the time, many people had predicted that once Biden took office and the vaccine was released, Covid would be declared to have been beaten. But that didn’t happen and mainly for one reason: resistance to the vaccine was more intense than anyone had predicted. The Biden administration attempted to impose mandates on the entire US workforce. Thanks to a Supreme Court ruling, that effort was thwarted but not before HR departments around the country had already implemented them. 

As the months rolled on – and four major cities closed all public accommodations to the unvaccinated, who were being demonized for prolonging the pandemic – it became clear that the vaccine could not and would not stop infection or transmission, which means that this shot could not be classified as a public health benefit. Even as a private benefit, the evidence was mixed. Any protection it provided was short-lived and reports of vaccine injury began to mount. Even now, we cannot gain full clarity on the scale of the problem because essential data and documentation remains classified. 

After four years, we find ourselves in a strange position. We still do not know precisely what unfolded in mid-March 2020: who made what decisions, when, and why. There has been no serious attempt at any high level to provide a clear accounting much less assign blame. 

Not even Tucker Carlson, who reportedly played a crucial role in getting Trump to panic over the virus, will tell us the source of his own information or what his source told him. There have been a series of valuable hearings in the House and Senate but they have received little to no press attention, and none have focus on the lockdown orders themselves. 

The prevailing attitude in public life is just to forget the whole thing. And yet we live now in a country very different from the one we inhabited five years ago. Our media is captured. Social media is widely censored in violation of the First Amendment, a problem being taken up by the Supreme Court this month with no certainty of the outcome. The administrative state that seized control has not given up power. Crime has been normalized. Art and music institutions are on the rocks. Public trust in all official institutions is at rock bottom. We don’t even know if we can trust the elections anymore. 

In the early days of lockdown, Henry Kissinger warned that if the mitigation plan does not go well, the world will find itself set “on fire.” He died in 2023. Meanwhile, the world is indeed on fire. The essential struggle in every country on earth today concerns the battle between the authority and power of permanent administration apparatus of the state – the very one that took total control in lockdowns – and the enlightenment ideal of a government that is responsible to the will of the people and the moral demand for freedom and rights. 

How this struggle turns out is the essential story of our times. 

CODA: I’m embedding a copy of PanCAP Adapted, as annotated by Debbie Lerman. You might need to download the whole thing to see the annotations. If you can help with research, please do.

*  *  *

Jeffrey Tucker is the author of the excellent new book 'Life After Lock-Down'

Tyler Durden Mon, 03/11/2024 - 23:40

Read More

Continue Reading

Government

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

Authored by Jack Phillips via The Epoch Times (emphasis ours),

A…

Published

on

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

Authored by Jack Phillips via The Epoch Times (emphasis ours),

A U.S. Centers for Disease Control (CDC) paper released Thursday found that thousands of young children have been taken to the emergency room over the past several years after taking the very common sleep-aid supplement melatonin.

The Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia, on April 23, 2020. (Tami Chappell/AFP via Getty Images)

The agency said that melatonin, which can come in gummies that are meant for adults, was implicated in about 7 percent of all emergency room visits for young children and infants “for unsupervised medication ingestions,” adding that many incidents were linked to the ingestion of gummy formulations that were flavored. Those incidents occurred between the years 2019 and 2022.

Melatonin is a hormone produced by the human body to regulate its sleep cycle. Supplements, which are sold in a number of different formulas, are generally taken before falling asleep and are popular among people suffering from insomnia, jet lag, chronic pain, or other problems.

The supplement isn’t regulated by the U.S. Food and Drug Administration and does not require child-resistant packaging. However, a number of supplement companies include caps or lids that are difficult for children to open.

The CDC report said that a significant number of melatonin-ingestion cases among young children were due to the children opening bottles that had not been properly closed or were within their reach. Thursday’s report, the agency said, “highlights the importance of educating parents and other caregivers about keeping all medications and supplements (including gummies) out of children’s reach and sight,” including melatonin.

The approximately 11,000 emergency department visits for unsupervised melatonin ingestions by infants and young children during 2019–2022 highlight the importance of educating parents and other caregivers about keeping all medications and supplements (including gummies) out of children’s reach and sight.

The CDC notes that melatonin use among Americans has increased five-fold over the past 25 years or so. That has coincided with a 530 percent increase in poison center calls for melatonin exposures to children between 2012 and 2021, it said, as well as a 420 percent increase in emergency visits for unsupervised melatonin ingestion by young children or infants between 2009 and 2020.

Some health officials advise that children under the age of 3 should avoid taking melatonin unless a doctor says otherwise. Side effects include drowsiness, headaches, agitation, dizziness, and bed wetting.

Other symptoms of too much melatonin include nausea, diarrhea, joint pain, anxiety, and irritability. The supplement can also impact blood pressure.

However, there is no established threshold for a melatonin overdose, officials have said. Most adult melatonin supplements contain a maximum of 10 milligrams of melatonin per serving, and some contain less.

Many people can tolerate even relatively large doses of melatonin without significant harm, officials say. But there is no antidote for an overdose. In cases of a child accidentally ingesting melatonin, doctors often ask a reliable adult to monitor them at home.

Dr. Cora Collette Breuner, with the Seattle Children’s Hospital at the University of Washington, told CNN that parents should speak with a doctor before giving their children the supplement.

“I also tell families, this is not something your child should take forever. Nobody knows what the long-term effects of taking this is on your child’s growth and development,” she told the outlet. “Taking away blue-light-emitting smartphones, tablets, laptops, and television at least two hours before bed will keep melatonin production humming along, as will reading or listening to bedtime stories in a softly lit room, taking a warm bath, or doing light stretches.”

In 2022, researchers found that in 2021, U.S. poison control centers received more than 52,000 calls about children consuming worrisome amounts of the dietary supplement. That’s a six-fold increase from about a decade earlier. Most such calls are about young children who accidentally got into bottles of melatonin, some of which come in the form of gummies for kids, the report said.

Dr. Karima Lelak, an emergency physician at Children’s Hospital of Michigan and the lead author of the study published in 2022 by the CDC, found that in about 83 percent of those calls, the children did not show any symptoms.

However, other children had vomiting, altered breathing, or other symptoms. Over the 10 years studied, more than 4,000 children were hospitalized, five were put on machines to help them breathe, and two children under the age of two died. Most of the hospitalized children were teenagers, and many of those ingestions were thought to be suicide attempts.

Those researchers also suggested that COVID-19 lockdowns and virtual learning forced more children to be at home all day, meaning there were more opportunities for kids to access melatonin. Also, those restrictions may have caused sleep-disrupting stress and anxiety, leading more families to consider melatonin, they suggested.

The Associated Press contributed to this report.

Tyler Durden Mon, 03/11/2024 - 21:40

Read More

Continue Reading

International

Red Candle In The Wind

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by…

Published

on

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by printing at 275,000 against a consensus call of 200,000. We say superficially, because the downward revisions to prior months totalled 167,000 for December and January, taking the total change in employed persons well below the implied forecast, and helping the unemployment rate to pop two-ticks to 3.9%. The U6 underemployment rate also rose from 7.2% to 7.3%, while average hourly earnings growth fell to 0.2% m-o-m and average weekly hours worked languished at 34.3, equalling pre-pandemic lows.

Undeterred by the devil in the detail, the algos sprang into action once exchanges opened. Market darling NVIDIA hit a new intraday high of $974 before (presumably) the humans took over and sold the stock down more than 10% to close at $875.28. If our suspicions are correct that it was the AIs buying before the humans started selling (no doubt triggering trailing stops on the way down), the irony is not lost on us.

The 1-day chart for NVIDIA now makes for interesting viewing, because the red candle posted on Friday presents quite a strong bearish engulfing signal. Volume traded on the day was almost double the 15-day simple moving average, and similar price action is observable on the 1-day charts for both Intel and AMD. Regular readers will be aware that we have expressed incredulity in the past about the durability the AI thematic melt-up, so it will be interesting to see whether Friday’s sell off is just a profit-taking blip, or a genuine trend reversal.

AI equities aside, this week ought to be important for markets because the BTFP program expires today. That means that the Fed will no longer be loaning cash to the banking system in exchange for collateral pledged at-par. The KBW Regional Banking index has so far taken this in its stride and is trading 30% above the lows established during the mini banking crisis of this time last year, but the Fed’s liquidity facility was effectively an exercise in can-kicking that makes regional banks a sector of the market worth paying attention to in the weeks ahead. Even here in Sydney, regulators are warning of external risks posed to the banking sector from scheduled refinancing of commercial real estate loans following sharp falls in valuations.

Markets are sending signals in other sectors, too. Gold closed at a new record-high of $2178/oz on Friday after trading above $2200/oz briefly. Gold has been going ballistic since the Friday before last, posting gains even on days where 2-year Treasury yields have risen. Gold bugs are buying as real yields fall from the October highs and inflation breakevens creep higher. This is particularly interesting as gold ETFs have been recording net outflows; suggesting that price gains aren’t being driven by a retail pile-in. Are gold buyers now betting on a stagflationary outcome where the Fed cuts without inflation being anchored at the 2% target? The price action around the US CPI release tomorrow ought to be illuminating.

Leaving the day-to-day movements to one side, we are also seeing further signs of structural change at the macro level. The UK budget last week included a provision for the creation of a British ISA. That is, an Individual Savings Account that provides tax breaks to savers who invest their money in the stock of British companies. This follows moves last year to encourage pension funds to head up the risk curve by allocating 5% of their capital to unlisted investments.

As a Hail Mary option for a government cruising toward an electoral drubbing it’s a curious choice, but it’s worth highlighting as cash-strapped governments increasingly see private savings pools as a funding solution for their spending priorities.

Of course, the UK is not alone in making creeping moves towards financial repression. In contrast to announcements today of increased trade liberalisation, Australian Treasurer Jim Chalmers has in the recent past flagged his interest in tapping private pension savings to fund state spending priorities, including defence, public housing and renewable energy projects. Both the UK and Australia appear intent on finding ways to open up the lungs of their economies, but government wants more say in directing private capital flows for state goals.

So, how far is the blurring of the lines between free markets and state planning likely to go? Given the immense and varied budgetary (and security) pressures that governments are facing, could we see a re-up of WWII-era Victory bonds, where private investors are encouraged to do their patriotic duty by directly financing government at negative real rates?

That would really light a fire under the gold market.

Tyler Durden Mon, 03/11/2024 - 19:00

Read More

Continue Reading

Trending